Phosphatidylinositol Containing Lipidic Particles Reduces Immunogenicity and Catabolism of Factor VIII in Hemophilia A Mice
- 2 June 2010
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (3), 473-481
- https://doi.org/10.1208/s12248-010-9207-z
Abstract
Factor VIII (FVIII) is an important cofactor in blood coagulation cascade. It is a multidomain protein that consists of six domains, NH2-A1-A2-B-A3-C1-C2-COOH. The deficiency or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding disorder. Replacement therapy using recombinant FVIII (rFVIII) is the first line of therapy, but a major clinical complication is the development of inhibitory antibodies that abrogate the pharmacological activity of the administered protein. FVIII binds to anionic phospholipids (PL), such as phosphatidylinositol (PI), via lipid binding region within the C2 domain of FVIII. This lipid binding site not only consists of immunodominant epitopes but is also involved in von Willebrand factor binding that protects FVIII from degradation in vivo. Thus, we hypothesize that FVIII–PL complex will influence immunogenicity and catabolism of FVIII. The biophysical studies showed that PI binding did not alter conformation of the protein but improved intrinsic stability as measured by thermal denaturation studies. ELISA studies confirmed the involvement of the C2 domain in binding to PI containing lipid particles. PI binding prolonged the in vivo circulation time and reduced catabolism of FVIII in hemophilia A mice. FVIII–PI complex reduced inhibitor development in hemophilia A mice following intravenous and subcutaneous administration. The data suggest that PI binding reduces catabolism and immunogenicity of FVIII and has potential to be a useful therapeutic approach for hemophilia A.Keywords
This publication has 66 references indexed in Scilit:
- Phosphatidylserine Containing Liposomes Reduce Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A**Karthik Ramani and Razvan D. Miclea contributed equally to the manuscript.Journal of Pharmaceutical Sciences, 2008
- Clearance mechanisms of von Willebrand factor and factor VIIIJournal of Thrombosis and Haemostasis, 2007
- Receptor‐mediated clearance of factor VIII: implications for pharmacokinetic studies in individuals with haemophiliaHaemophilia, 2006
- Aggregation Kinetics of Recombinant Human FVIII (rFVIII)Journal of Pharmaceutical Sciences, 2005
- Lipid Binding Region (2303–2332) is Involved in Aggregation of Recombinant Human FVIII (rFVIII)**Karthik Ramani and Vivek S. Purohit have contributed equally to this work.Journal of Pharmaceutical Sciences, 2005
- T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjectsJournal of Thrombosis and Haemostasis, 2004
- Epitope repertoire of human CD4 T cells on the A3 domain of coagulation factor VIIIJournal of Thrombosis and Haemostasis, 2004
- Uptake of Liposomes Containing Phosphatidylserine by Liver Cellsin Vivoand by Sinusoidal Liver Cells in Primary Culture:In Vivo–in VitroDifferencesBiochemical and Biophysical Research Communications, 1999
- Sequence of the Murine Factor VIII cDNAGenomics, 1993
- Clinical Pharmacokinetics of Factor VIII in Patients with Classic HaemophiliaClinical Pharmacokinetics, 1987